TD Cowen analyst Ritu Baral downgraded Morphic Therapeutic (NASDAQ: MORF) from Buy to Hold.The analyst commented, "This AM, LLY announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE